80% of China’s Clinical Trial Data Fraudulent!

A recent investigation of 1622 new drugs submitted to China’s State Food and Drug Administration (CFDA) has found that 1308 of those applications should be withdrawn for containing fabricated, flawed, or inadequate data from clinical trials. Find out more here. (Source: thebmj, October 2016)

You might also be interested in:

NPC's Dubois: Article's Authors 'Used Flawed Data' March 13, 2019
RWE: Opportunity, Challenges and Sourcing Simplified November 30, 2018
Report: Generic 'Cartel' Probe Expands to 300 Drugs December 10, 2018
Pharmacy Benefit Managers: A Mechanism for Containing Costs or… October 1, 2018
Social Media Could Become Significant Disruptor in Clinical Trials November 19, 2018
Joint Investigation Finds Medical Journals Should Bolster… December 10, 2018
Benchmarking Market Access Strategies for High-Cost Drugs and… August 21, 2018